Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5070/D330163303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World Cohort.
Clin Lymphoma Myeloma Leuk
August 2025
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:
Background: Mogamulizumab is more effective in treating the blood component of mycosis fungoides (MF) and Sezary syndrome (SS), though some patients also experience significant skin improvement. The characteristics distinguishing those with a favorable skin response remain unclear.
Objectives: This study aimed to characterize MF/SS patients achieving skin response on mogamulizumab.
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.
Clin Lymphoma Myeloma Leuk
August 2025
The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, KS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; U.S Myeloma Innovations Research Collaborative, Kansas City, KS. Electronic addres
Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) remains the only curative option for myelofibrosis (MF) but is often underutilized in patients aged ≥ 65 due to concerns about treatment-related toxicity.
Methods: We conducted a retrospective analysis of chronic-phase MF allo-HCT recipients using the publicly available CIBMTR P-5640 dataset (2008-2019). Key endpoints included overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-vs-host disease (GVHD)-related outcomes.
Impact of Measurable Residual Disease Status on Outcomes After HLA-Matched Donor Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk
August 2025
The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, KS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; U.S Myeloma Innovations Research Collaborative, Kansas City, KS. Electronic addres
Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a key treatment for acute myeloid leukemia (AML). Measurable residual disease (MRD) predicts post-transplant outcomes. This study evaluates the impact of pretransplant MRD status on outcomes in AML patients undergoing allo-HCT.
View Article and Find Full Text PDF[Diagnosis of non-autoimmune hemolysis in the adult].
Rev Med Interne
September 2025
Service d'hématologie biologique, CHU d'Amiens-Picardie, Amiens, France; HEMATIM UR4666, université Picardie Jules-Verne, Amiens, France.
The diagnosis of hemolysis is still based on straightforward biochemical parameters: haptoglobin (the most sensitive), lactate dehydrogenase (LDH), and unconjugated bilirubin. Anemia is not always present. Reticulocyte counts typically exceed 120×10/L, except in cases of associated vitamin deficiency or during the very early phase of acute hemolysis.
View Article and Find Full Text PDFWomen's knowledge concerning the impact of chronic systemic diseases and related treatments on pregnancy.
Rev Med Interne
September 2025
Service de médecine interne, centre hospitalier universitaire de Poitiers, 2, rue de la Milétrie, 86000 Poitiers, France; Université de médecine et de pharmacie, université de Poitiers, Poitiers, France; Inserm U1313, université de Poitiers, Poitiers, France.
Introduction: Many women of childbearing age are being treated for chronic conditions that require long-term medication. We assessed the knowledge of women being treated in internal medicine and clinical immunology, regarding the impact of their disease and specific treatments on a potential pregnancy.
Methods: Between September 1st, 2019, and November 1st, 2020, in four hospitals in the Poitou-Charentes region, a questionnaire was given to every woman aged 18 to 44 who came in for an internal medicine and clinical immunology consultation for the follow-up of a chronic systemic disease.